0.5 mg/kg/day tapered over 42 days versus 18-day taper versus placebo
Intact survival (IQ > 70, normal neurologic exam, regular classroom): 69% versus 25% (18-d course) versus 18% (placebo) ()
Jones and the Collaborative Dexamethasone Trial Follow-up Group , 13–17 years
At 2–12 wk
0.5 mg/kg/day for 7 days
No difference in moderate/severe disability (defined as IQ > 2 SDs < mean, CP, hearing or vision loss); CP: 24% versus 15% (relative risk: 1.58 [95% confidence interval: 0.81–3.07])
NDI: neurodevelopmental impairment; PDI: psychomotor developmental index; NS: not significant.
We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.